Ipamorelin and GHRP-6 are both synthetic growth hormone secretagogues that act on the ghrelin receptor (GHS-R1a) to stimulate GH release from the anterior pituitary. They are among the most studied GHRP compounds in the preclinical literature, yet their pharmacological profiles differ in ways that are directly relevant to research design. Ipamorelin is a third-generation GHRP prized for its selectivity, while GHRP-6 is a first-generation hexapeptide with broader effects — including potent appetite stimulation — that give it a distinct research utility.
For researchers choosing between these two compounds or designing studies that use both, understanding the differences in receptor selectivity, GH pulse kinetics, and off-target hormonal effects is essential for accurate data interpretation and valid experimental design. This guide compares Ipamorelin and GHRP-6 across the dimensions most relevant to preclinical and translational research.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed as a selective GHS-R1a agonist. It was engineered specifically to maximize GH-releasing potency while minimizing stimulation of other pituitary hormones — most notably ACTH/cortisol and prolactin, which earlier GHRPs stimulated as secondary effects. Published research has consistently confirmed this selectivity profile, establishing Ipamorelin as the cleanest pharmacological tool among the GHRP class for isolating GH axis-specific effects.
| Property | Value |
|---|---|
| Molecular formula | C₃₈H₄₉N₉O₅ |
| Molecular weight | 711.86 g/mol |
| CAS number | 170851-70-4 |
| Generation | Third-generation GHRP |
| Half-life (plasma) | ~2 hours |
| GH selectivity | High — minimal cortisol/prolactin effect |
| Appetite stimulation | Minimal |
| Physical form | White lyophilized powder |
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a first-generation synthetic hexapeptide with a long research history dating to the 1980s. It produces robust GH release through GHS-R1a agonism but with broader off-target endocrine effects compared to later-generation GHRPs. Its potent appetite-stimulating effect — a direct consequence of GHS-R1a activation in hypothalamic feeding circuits — makes it both a useful research tool in feeding behavior studies and a confounding variable in body composition experiments.
| Property | Value |
|---|---|
| Molecular formula | C₄₆H₅₆N₁₂O₆ |
| Molecular weight | 873.01 g/mol |
| CAS number | 87616-84-0 |
| Generation | First-generation GHRP |
| Half-life (plasma) | ~15–60 minutes |
| GH selectivity | Moderate — notable cortisol/prolactin effects |
| Appetite stimulation | Pronounced |
| Physical form | White lyophilized powder |
The most clinically significant difference between Ipamorelin and GHRP-6 in research contexts is their selectivity at GHS-R1a relative to downstream hormonal effects. While both compounds bind GHS-R1a with high affinity and stimulate GH release, GHRP-6 administration produces dose-dependent increases in plasma ACTH and cortisol — effects that are absent or negligible with Ipamorelin at equivalent GH-stimulating doses in the published literature.
Research comparing the two compounds directly has documented that GHRP-6 elevates cortisol by 30–60% above baseline at doses producing maximal GH responses, while Ipamorelin produces no statistically significant cortisol elevation at any dose tested in controlled studies. This difference is attributed to distinct receptor coupling profiles at the somatotroph versus corticotroph cell populations, and to GHRP-6’s additional activity at non-GHS-R1a targets that influence ACTH release.
Prolactin is similarly elevated by GHRP-6 but not Ipamorelin. Researchers designing studies where cortisol or prolactin elevation would confound outcomes — including immune function studies, metabolic studies, and stress response research — should use Ipamorelin to isolate GH-specific effects. GHRP-6 is the appropriate choice when studying the integrated hormonal response to GHS-R1a activation, or when appetite and orexigenic signaling are research endpoints.
Studies directly measuring GH secretory responses have documented that GHRP-6 and Ipamorelin produce broadly similar peak GH amplitudes at maximal effective doses, but with differences in the shape of the GH pulse and in dose-response relationships. GHRP-6 tends to produce slightly higher peak GH levels in some rodent studies, a finding attributed to its additional interactions with non-GHS-R1a pathways that contribute a small supplementary GH-releasing signal.
Both compounds exhibit synergy with GHRH-receptor agonists. Combination studies pairing either GHRP with CJC-1295 or Sermorelin have documented GH responses substantially greater than either compound alone — a synergy that reflects the dual-pathway (GHRHR and GHS-R1a) nature of GH secretion regulation. This synergistic profile is observed with both Ipamorelin and GHRP-6, making both suitable for combination research designs examining GHRP/GHRH axis interactions.
GHRP-6’s pronounced appetite-stimulating effect is mechanistically distinct from its GH-releasing activity, though both are mediated through GHS-R1a. The ghrelin receptor in hypothalamic arcuate nucleus neurons drives orexigenic signaling — increasing neuropeptide Y and agouti-related protein expression — when activated by GHRP-6. This appetite effect is one of the most reproducible findings in GHRP research and has made GHRP-6 a standard tool compound in feeding behavior and energy homeostasis research.
Ipamorelin’s minimal appetite effect reflects its more restrictive receptor interaction profile — it activates GHS-R1a-mediated somatotroph signaling efficiently without producing the full spectrum of downstream GHS-R1a-dependent behaviors that GHRP-6 elicits. Researchers studying body composition, metabolic rate, or GH-driven changes in tissue remodeling who wish to avoid appetite confounds should use Ipamorelin. Researchers specifically investigating ghrelin receptor-mediated feeding behavior benefit from GHRP-6’s reliable orexigenic signal.
GHRP-6 has accumulated a body of preclinical literature documenting GH-independent cytoprotective effects — particularly in cardiac and hepatic tissue. Research has demonstrated GHRP-6 activation of the CD36 receptor on cardiomyocytes, producing anti-apoptotic and anti-inflammatory effects in ischemia-reperfusion models independent of GH secretion. This non-GH mechanism is shared to some extent with Hexarelin (another first-generation GHRP) but has not been demonstrated for Ipamorelin, which lacks significant CD36 binding activity.
Researchers examining cytoprotective mechanisms in cardiac, hepatic, or neural tissue models may find GHRP-6’s broader receptor interaction profile advantageous. Researchers who need a clean GH secretagogue without these additional biological activities should use Ipamorelin.
The choice between Ipamorelin and GHRP-6 should be driven by the specific research question. For studies examining GH axis pharmacology, body composition changes attributable to GH/IGF-1 signaling, or combination GH secretagogue protocols — Ipamorelin is the preferred compound because its selective profile allows clean attribution of effects to GH pathway activation.
For studies examining the full spectrum of GHS-R1a biology — including appetite regulation, integrated hormonal responses, and potential GH-independent cytoprotective mechanisms — GHRP-6 provides a broader experimental readout. Its longer research history also provides a larger published literature base for historical comparison of results.
When studying GHRP effects on body composition in animal models, the pronounced appetite stimulation of GHRP-6 requires careful experimental control — pair-feeding designs or food intake monitoring are essential to isolate the direct metabolic effects of GH elevation from the secondary effects of increased caloric consumption. This confound does not apply with Ipamorelin, simplifying experimental design in studies where appetite effects are not a primary endpoint.
Both Ipamorelin and GHRP-6 act as agonists of the ghrelin receptor (GHS-R1a), a Gq-protein-coupled receptor expressed in the anterior pituitary, hypothalamus, hippocampus, cardiac tissue, and gastrointestinal tract. Receptor activation initiates IP3-mediated calcium release and PKC activation in somatotrophs, triggering GH exocytosis. The two compounds share this core mechanism but differ in their additional receptor interactions and the downstream consequences of GHS-R1a activation in non-pituitary cell populations.
The structural basis for Ipamorelin’s selectivity has been characterized by receptor binding and mutagenesis studies showing that its compact pentapeptide structure engages a more restricted binding interface at GHS-R1a compared to GHRP-6’s hexapeptide structure. This narrower binding footprint limits activation of alternative signaling pathways accessible through the full binding cavity, producing the selectively GH-stimulating phenotype that characterizes Ipamorelin research.
Official Peptides supplies both Ipamorelin and GHRP-6 at >99% purity verified by HPLC, with batch-specific certificates of analysis from independent third-party laboratories. Both compounds ship cold-pack from our US facility with same-day dispatch on qualifying orders. For researchers running parallel experiments with both compounds, bundle ordering is available with free shipping on orders over $150.
Order Ipamorelin from Official Peptides →
Order GHRP-6 from Official Peptides →
Official Peptides supplies research-grade Ipamorelin and GHRP-6 with >99% HPLC purity and third-party COA on every batch. US domestic shipping 2–5 business days. For research use only.
All content is provided for research reference purposes only. For in vitro laboratory research use only.